摘要
目的 比较多西他赛分别与奥沙利铂和卡铂联合治疗晚期非小细胞肺癌的疗效和不良反应,为安全用药提供参考.方法 52 例晚期非小细胞肺癌患者随机分为2 组.多西他赛/ 奥沙利铂组：多西他赛75mg/m2,静脉滴注,d1;奥沙利铂120mg/m2,静脉滴注,持续2h,d1.多西他赛/ 卡铂组：多西他赛用法同前,卡铂AUC =5 mg /（mL · min）,静脉滴注,d1.两种方案均21d 为一周期,2～4 周期后评价疗效.结果 多西他赛/ 奥沙利铂组中8 例达到部分缓解,有效率为30.77%,临床获益率84.62%;多西他赛/ 卡铂组7 例达到PR,有效率为30.43%,临床获益率86.96%.两组疗效比较差异无统计学意义（P 〉0.05）,Ⅲ、Ⅳ度毒副反应发生率,多西他赛/ 奥沙利铂组组低于多西他赛/ 卡铂组,差异有统计学意义（P ＜ 0.05）.结论 多西他赛联合奥沙利铂方案治疗晚期非小细胞肺癌是一个疗效较好、毒性较低的方案,值得推广应用.
Objective To compare the response and toxic reaction of docetaxel combined with oxaliplatin or carboplatin in patients with advanced non-small cell lung cancer so that providing reference for the safe use of pesticides. Methods 52 patients with advanced non-small cell lung cancer were randomly divided into 2 groups. In the docetaxel combined with oxaliplatin group, the patients were given docetaxel 75mg/m2 and oxaliplatin 120mg/m2 on day 1. In the docetaxel combined with carboplatin group, the patients were given docetaxel 75mg/m2 and carboplatin AUC =5mg/ （mL-min） on day 1. One cycle are 21 days in the two schemes. The clinical responses were assessed after two or four cycles. Results There were 8 cases reached some mitigation and the efficient rate and clinical benefit rate were respectively 30.77% and 84.62% in Docetaxel/Oxaliplatin Group, In another group there were 7cases reached some mitigation and the efficient rate and clinical benefit rate were respectively 30.43% and 86.96%. There is no statistical differences between the two groups （P 〉 0,05） , The docetaxel/Oxaliplatin group has lower incidence of Ⅲ or Ⅳ degrees of side effects than the docetaxel/carboplatin group. The difference has stastical significance （P〈0.05） . Conclusion Docetaxel and Oxaliplatin chemotherapy for patients with advanced non-small cell lung cancer is one of the better, less toxic treatments, which is worth to application widely.
出处
《中国医药指南》
2012年第19期26-27,共2页
Guide of China Medicine
关键词
非小细胞肺癌
化疗
多西他赛
奥沙利铂
卡铂
疗效
Non-small cell lung cancer
Chemotherapy
Docetaxel
Oxaliplatin
Carboplatin
Curative effect
